Alvotech Up 4% On Marketing Approval Of AVT04 In Japan

Shares of Alvotech (ALVO have increased by 4% on Monday following news that its commercialization partner in Japan, Fuji Pharma Co., Ltd., has received approval to market AVT04 (ustekinumab), a biosimilar to Stelara, from the Japanese Ministry of Health, Labor and Welfare.

Related Keywords

China ,Japan ,Japanese ,Chinese , ,Fuji Pharma Co Ltd ,Japanese Ministry Of Health ,Nasdaq ,Japanese Ministry ,Biosimilar ,Alvotech ,Uji Pharma ,Avt04 ,